XML 53 R17.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2020

Related Party Transactions [Abstract]

Related Party Transactions

9.	Related Party Transactions

Astellas is an equity investor in the Company and considered a related party. The Company recorded revenue related to collaboration agreements with Astellas of $4.7 million and $15.5 million for the three months ended September 30, 2020 and 2019, respectively, and $14.2 million and $155.0 million for the nine months ended September 30, 2020 and 2019, respectively.

The drug product revenue from Astellas for the three months ended September 30, 2020 represented a change in estimated variable consideration at the time an updated listed price for roxadustat was issued by the Japanese Ministry of Health, Labour and Welfare, which resulted in a $4.0 million reduction to revenue, related to roxadustat API sales in 2018. See Note 3, Collaboration Agreements and Revenues, for details. The drug product revenue from Astellas for the nine months ended September 30, 2020 was $4.3 million, as the Company recorded $8.2 million drug product revenue from Astellas in the second quarter of 2020.

The Company recorded expense related to collaboration agreements with Astellas of $0.2 million and $0.9 million during the three months ended September 30, 2020 and 2019, respectively, and $0.5 million and $2.2 million during the nine months ended September 30, 2020 and 2019, respectively.

As of September 30, 2020 and December 31, 2019, accounts receivable from Astellas were $4.7 million and $4.8 million, respectively, and amounts due to Astellas were $4.1 million and $36.9 million, respectively, which included $4.0 million and $36.3 million of changes in estimated variable consideration related to the API product revenue recognized in 2018, at the time the roxadustat listed price was issued or updated by the Japanese Ministry of Health, Labour and Welfare in the first quarter of 2020 and the fourth quarter of 2019. The $36.3 million was fully paid during the first quarter of 2020.

Prepaid expenses and other current assets as of December 31, 2019 included $125.2 million of net unbilled contract assets from Astellas, representing a $130.0 million unbilled contract asset related to two regulatory milestones under the Europe Agreement with Astellas associated with the planned MAA submission to the EMA, net of $4.8 million of associated deferred revenue. According to the Europe Agreement, this $130.0 million was billed to Astellas upon the submission of an MAA in the second quarter of 2020. See Note 3, Collaboration Agreements and Revenues, for details.

In September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which was determined to be an unconsolidated VIE. As such, Falikang is accounted for as an equity method investment, and considered as a related party to the Company. The Company’s investment in Falikang was approximately $1.5 million, which is the total of the 51.1% of Falikang’s equity and the acquisition costs. In addition, the Company recognized its proportionate share of the reported profits or losses of Falikang, beginning September 15, 2020, as other income (loss) in the condensed consolidated statement of operations, and as an adjustment to its investment in unconsolidated subsidiary in the condensed consolidated balance sheet. Falikang has not incurred material profit or loss to date. As of September 30, 2020, the Company’s other assets included $1.5 million of its equity investment in Falikang, and prepaid expenses and other current assets included its miscellaneous receivables of $0.2 million from Falikang. See Note 2, Acquisition and Variable Interest Entity, for details.